Table 2.

Overlap between drug candidates identified by the CANDO platform and those identified by Kouznetsova et al. [27].

Compound(s)	Interaction Score	Consensus Score	Approved Indication	Mode of Action
Niclosamide *	1.897	3	helminthic infestation	inhibits parasite metabolism
Sertraline *	1.897	1	depression, anxiety	selective serotonin receptor inhibitor
Clomifene *	1.897	1	anovulation, oligoovulation	selective estrogen receptor modulator
Alverine	1.897	1	gastrointestinal muscle spasms	parasympathetic nervous system modulator
Aprindine	1.897	1	cardiac arrhythmia	sodium channel inhibitor
Mebendazole *	1.897	1	helminthic infestation	tubulin destabilizer
Salmeterol	1.890	2	asthma	beta 2 adrenergic receptor agonist
Topotecan	1.823	1	ovarian and lung cancers	DNA topoisomerase I inhibitor
Deslanoside *	1.377	10	cardiac arrhythmia	sodium-potassium channel blocker
Propafenone	1.298	10	cardiac arrhythmia	sodium channel blocker
Digoxin *	1.067	1	cardiac arrhythmia	sodium-potassium channel blocker
Proglumetacin	1.058	1	non-steroidal anti-inflammatory drug	cyclooxygenase-1 inhibitor
Posaconazole	1.023	3	fungal infection (aspergillus and candida)	membrane bound enzyme inhibitor
Raloxifene *	0.843	2	osteoporosis and breast cancer prevention	selective estrogen receptor modulator
Clarithromycin	0.741	2	bacterial infections	protein synthesis inhibitor
Clemastine *	0.741	1	allergies	H1 histamine receptor inhibitor
Colchicine	0.741	1	gout, pericarditis	microtubule inhibitor
Tamoxifen *	0.741	1	estrogen receptor positive breast cancer	Selective estrogen receptor modulator
Thiothixene	0.741	1	psychotic disorders, e.g., schizophrenia	dopamine antagonist
Daunorubicin	0.714	1	hematologic dyscrasia (acute lymphocytic leukemia, acute myeloid leukemia)	DNA topoisomerase II inhibitor
Dronedarone	0.722	1	cardiac arrhythmia	potassium channel blocker
Vincristine	0.707	1	hematologic dyscrasia (acute lymphocytic leukemia, acute myeloid leukemia)	microtubule inhibitor

* Drugs also identified by Johansen et al. [28].